Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma

por Dosani, T, Covut, F, Beck, R, Driscoll, J J, de Lima, M, Malek, E
Publicado 2017

Metabolic tumor volume on interim PET is a better predictor of outcome in diffuse large B-cell lymphoma than semiquantitative methods

por Malek, E, Sendilnathan, A, Yellu, M, Petersen, A, Fernandez-Ulloa, M, Driscoll, J J
Publicado 2015

Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib

por Jagannathan, S, Abdel-Malek, M A Y, Malek, E, Vad, N, Latif, T, Anderson, K C, Driscoll, J J
Publicado 2015

A new pharmacokinetic model for (90)Y-ibritumomab tiuxetan based on 3-dimensional dosimetry

por Morschhauser, F., Dekyndt, B., Baillet, C., Barthélémy, C., Malek, E., Fulcrand, J., Bigot, P., Huglo, D., Décaudin, B., Simon, N., Odou, P.
Publicado 2018

Pharmacogenomics and chemical library screens reveal a novel SCF(SKP2) inhibitor that overcomes Bortezomib resistance in multiple myeloma

por Malek, E, Abdel-Malek, M A Y, Jagannathan, S, Vad, N, Karns, R, Jegga, A G, Broyl, A, van Duin, M, Sonneveld, P, Cottini, F, Anderson, K C, Driscoll, J J
Publicado 2017